Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 History  





2 References  





3 External links  














Alcon






العربية
Dansk
Deutsch
فارسی
Français
Galego

Bahasa Indonesia
Italiano
مصرى
Bahasa Melayu

Português
Русский
Саха тыла
Suomi
ி
Türkçe
Українська
Tiếng Vit

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Alcon Inc.

Native name

Alcon AG
Company typePublic (Aktiengesellschaft)

Traded as

  • NYSEALC
  • IndustryOphthalmology
    Founded1945; 79 years ago (1945)inFort Worth, Texas, United States
    Headquarters ,
    United States

    Key people

    David Endicott (CEO)
    Products
  • Contact lenses
  • Over-the-counter products
  • RevenueIncrease US$9.46 billion (2023)

    Operating income

    Increase US$1.04 billion (2023)

    Net income

    Increase US$974 million (2023)
    Total assetsIncrease US$29.6 billion (2023)
    Total equityIncrease US$20.6 billion (2023)

    Number of employees

    25,315 (FTE, 2023)
    Websitealcon.com
    Footnotes / references
    [1]
    Alcon offices in Johns Creek, Georgia

    Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.[2]

    Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company.[3][4] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.[5]

    History[edit]

    Alcon was founded in 1945 as a small pharmacy in Fort Worth, Texas, United States. It was named for its founders, pharmacists Robert Alexander and William Conner[6] who focused on sterile ophthalmic products.

    NestléofSwitzerland purchased Alcon in 1977.[7] Alcon expanded its manufacturing capability with new plants in South America and Europe and drastically increased its investment in research.[8][9]

    In 1979, Alcon acquired Texas Pharmacal Company which became Dermatological Products of Texas (and is now DPT Laboratories).[10]

    In 1984, Alcon founded the Technical Excellence Award to promote achievements in R&D excellence and has awarded it to more than 100 recipients. The Alcon product line has expanded from pharmaceuticals to the surgical arena. Today, Alcon has operations in 75 countries and its products are sold in over 180 countries.

    Nestlé conducted an initial public offering of 25% of its stake in Alcon in 2002. The stock is traded under the ticker symbol ALC. In July 2008, Novartis purchased approximately 25% of Nestlé's stake in Alcon, with an option to buy Nestlé's remaining shares beginning in 2010.[11] Novartis bought 52% stake from Nestlé for $28.1 Billion. This deal brought the total ownership of Alcon by Novartis to 77%. Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon.[12][13]

    On March 29, 2010, Alcon acquired Durezol and Zyclorin from Sirion Therapeutics. Alcon received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics.[14]

    On June 28, 2010, Alcon's Independent Director Committee announced that a recommendation by the committee was an indispensable first step before the board of the company can decide on the merger proposal of Novartis AG, refuted Novartis’ public implications that it would be able to unilaterally impose the merger irrespective of the Independent Director Committee's position once Novartis became Alcon's majority shareholder. On July 8, 2010, Alcon's independent director committee (IDC) had set up a $50 million litigation trust to ensure company's minority shareholders get the best deal from bidder Novartis AG.[15]

    On April 9, 2019, Alcon completed a 100% spin-off from Novartis.[4][16][17] The new standalone company is worth up to 28 billion Swiss francs.[18]

    In November 2021, Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least $475 million.[19] In August 2022, Alcon agreed to buy Aerie Pharmaceuticals for US$770 million to enhance its ophthalmic pharmaceutical portfolio.[20][21][22]

    References[edit]

    1. ^ "Alcon Inc. 2023 Annual Report (Form 20-F)". SEC.gov. U.S. Securities and Exchange Commission. 2024-02-27.
  • ^ Bounds, Jeff (2020-01-22). "The (Alcon) Family Tree: How One Company Seeded a DFW Life Science Legacy". Dallas Innovates. Retrieved 2023-02-28.
  • ^ "Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business". Alcon.
  • ^ a b Smith, Anna (2019-04-10). "Novartis continues to 'reimagine' itself, as Alcon spin-off completed". PharmaTimes. Retrieved 2019-04-10.
  • ^ "Oberpfälzer Adresse für Augen-Korrektur". www.onetz.de (in German). Retrieved 2020-10-20.
  • ^ "Improving Vision through Innovation Since 1945".
  • ^ Nicholson, Chris (4 January 2010). "Novartis to Buy Majority of Alcon From Nestlé". The New York Times. Archived from the original on 6 January 2014.
  • ^ "Alcon considering $100 million manufacturing expansion in south Fort Worth". KERA News. 2023-10-24. Retrieved 2024-03-10.
  • ^ "Alcon eyes new $100 million manufacturing plant in Fort Worth". Dallas News. 2023-10-23. Retrieved 2024-03-10.
  • ^ Taylor, Lisa (28 July 2002). "Permeating a market". San Antonio Business Journal.
  • ^ "Reuters - Novartis announces offer to buy Nestlé's shares in Alcon". [dead link]
  • ^ "Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business". Scribd.
  • ^ News Media, A. B. C. "Boston Beer, Urban Outfitters fall, Alcon, Axon Enterprise rise, Wednesday, 2/28/2024". ABC News. Retrieved 2024-03-10.
  • ^ "Alcon Completes Acquisition of Durezol™ and Zyclorin™ from Sirion". Business Wire. March 29, 2010. Retrieved March 16, 2016.
  • ^ "Alcon (ACL) Sets up trust for litigation between with Novartis to protect minorities". The Chief Executive Forum. Archived from the original on 2010-07-10.
  • ^ "Alcon tops $28 billion market cap in decade's biggest Swiss stock deal". Reuters. 2019-04-09. Retrieved 2019-04-10.
  • ^ "Novartis completes Alcon spin-off". www.healio.com. April 9, 2019. Retrieved 2020-02-25.
  • ^ Smith, Anna (2019-04-10). "Novartis continues to 'reimagine' itself, as Alcon spin-off completed". PharmaTimes. Retrieved 2020-01-30.
  • ^ "Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis". Reuters. 8 November 2021.
  • ^ "Alcon buys the American Aerie Pharmaceuticals for 770 million". Swissinfo (in French). 23 August 2022.
  • ^ News Media, ABC. "Boston Beer, Urban Outfitters fall, Alcon, Axon Enterprise rise, Wednesday, 2/28/2024". ABC News. Retrieved 2024-03-10.
  • ^ "Alcon posts 2024 outlook, quarterly numbers in line with market view". Reuters.
  • External links[edit]

  • Alcon Official Website
  • Alcon : Novartis exercises option and proposes merger
  • Novartis needs Alcon directors' OK for buyout
  • Swiss Corporate Governance Expert Supports Alcon Independent Director Committee’s Position against Novartis [dead link]

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Alcon&oldid=1230446608"

    Categories: 
    Alcon
    Pharmaceutical companies established in 1945
    Companies based in Fort Worth, Texas
    Pharmaceutical companies of Switzerland
    Multinational companies
    Contact lenses
    Pharmaceutical companies of the United States
    Companies listed on the New York Stock Exchange
    Companies listed on the SIX Swiss Exchange
    Companies in the Swiss Market Index
    Life sciences industry
    Health care companies based in Texas
    Eyewear companies of the United States
    Novartis
    2010 mergers and acquisitions
    2002 initial public offerings
    Hidden categories: 
    Pages with non-numeric formatnum arguments
    CS1 German-language sources (de)
    All articles with dead external links
    Articles with dead external links from July 2021
    CS1 French-language sources (fr)
    Articles with short description
    Short description is different from Wikidata
    Articles containing German-language text
    Commons category link is on Wikidata
    Articles with dead external links from March 2015
    Articles with VIAF identifiers
     



    This page was last edited on 22 June 2024, at 19:10 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki